Zacks Investment Research
30 Dec 2025, 14:01 UTC · 38w ago
Verdict
Headline takes no side. We score KYTX +1.00 across three claims — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Kyverna Therapeutics' miv-cel achieved highly statistically significant improvements in primary and secondary endpoints for stiff person syndrome (SPS) in a pivotal phase II study.
More positive than 93% of claims this week
Kyverna plans to file a biologics license application (BLA) for miv-cel for the treatment of SPS in the first half of 2026.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 77% of claims this week
Interim data from a phase II/III study for generalized myasthenia gravis (gMG) demonstrated miv-cel's potential for durable, drug-free remission.
More positive than 64% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
The company announced positive top-line data from a pivotal phase II study and experienced a 41% stock price increase.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
1h ago
−26.3%
Price is moving against the score
$6.99 vs $9.49 close before publication (Dec 29) · not market-adjusted
KYTX chart →
